THE BANGKOK DECLARATION ON FREE TRADE AGREEMENTS & ACCESS TO MEDICINES MAY 2011

In 2001, World Trade Organization (WTO) members agreed to the Doha Declaration which affirmed that the Trade-
Related Aspects of Intellectual Property Rights (TRIPS) Agreement “can & should be interpreted & implemented in a
manner supportive of WTO member’s right to protect public health &, in particular, to promote access to medicines
for all.” Yet throughout the world, on a country-by-country basis, nations are being pushed to trade away their right
to do just this.
Negotiating governments are falsely promising that these agreements will not impact our health – yet we know this
is NOT true. The implementation of the TRIPS Agreement is already restricting access to newer medicines in the
Global South; FTA negotiations are threatening to make an already bad situation, worse. Evidence from existing FTAs
shows that they are undermining the rights of countries to implement domestic policies aimed at fulfilling the right
to health. Studies show that FTAs with US resulted in 79% of 103 off-patent medicines not having any generic
equivalent in Jordan & in price differences of up to 845,000% in the same therapeutic segment in Guatemala.
In the European Free Trade Agreements, the United States Trans Pacific Partnership Agreement, & a wide variety
of bilateral negotiations we know that intellectual property & investment chapters have been tabled that would
force sweeping changes in national laws making medicines unaffordable & unavailable in the future. The ability of
India & other countries with domestic manufacturing capacity to make low-cost medicines dictates who can &
cannot access life-saving medicines. Restricting generic production costs lives.
We stand in opposition to any & all proposals that negatively impact access to medicines in these FTAs including:

DATA EXCLUSIVITY that prevents governments from relying on clinical trial data to register generic versions of
medicines even if they are off-patent, their patents have expired or are revoked & complicates the issuance of
compulsory licences.

PATENT TERM EXTENTIONS that extend patent life beyond 20 years.
INCREASING PATENT SCOPE that significantly increases the number of medicines under patent by forcing
governments to give 20-year monopolies on new uses & new forms of old medicines thus allowing the extension
of monopolies on these medicines by a decade or more through minor changes in drug formulation or process.
PATENT LINKAGE that prevents the registration of generic versions of patented medicines and undermines the
early working & research exceptions thus delaying generic entry even when a compulsory licence is issued, the
patent expires or is revoked.

RESTRICTIONS ON COMPULSORY LICENCES that seek to limit the right of all countries to use compulsory
licences to ensure access to medicines for all even though this right has been repeatedly affirmed by
international treaties and declarations.

RESTRICTIONS ON PARALLEL IMPORTS that prevent the import of the cheapest priced patented medicines from
anywhere in the world.

INVESTMENT RULES that allow foreign companies to sue governments in private international arbitration over
domestic health policies like compulsory licences, health safeguards in patent laws, price reduction measures &
may prevent governments from promoting local production.

BORDER MEASURES that will deny medicines to patients in other developing countries with custom officials
seizing generic medicines being imported, in transit or that are being exported.

INJUNCTIONS that undermine the independence of the judiciary in developing countries to place the right to
health of patients over profits of multinational companies.

OTHER IP ENFORCEMENT MEASURES that put third parties like treatment providers at risk of police actions &
court cases and draws the whole manufacturing, distribution & supply chain for generic medicines into litigation.
We also stand in opposition to all other bullying tactics employed by developed countries & multinational
companies to pressure developing countries to adopt such harmful laws & policies including through the US Special
301 report, training of judges & government officials, continuous litigation & other forms of lobbying & pressure.
We call on:

The GOVERNMENTS OF THE UNITED STATES, EUROPEAN UNION, SWITZERLAND, NORWAY, ICELAND,
LIECHTENSTEIN, JAPAN, NEW ZEALAND, AUSTRALIA, & all other developed countries to immediately withdraw any
and all TRIPS-plus provisions in intellectual property and investment chapters in FTA negotiations, to immediately
cease all other forms of pressure & lobbying with developing & least developed countries and to scrap ACTA.

NATIONAL GOVERNMENTS IN THE GLOBAL SOUTH to band together & refuse to accept any further restrictions on
production, registration, supply, import or export of generic medicines; to launch South-South collaboration on an
urgent basis to put in place a sustainable, affordable pipeline of generic medicines for future generations; call for an
immediate review of TRIPS & its impact on access to medicines in developing & least developed countries.

GOVERNMENTS IN THE GLOBAL SOUTH THAT HAVE ALREADY SIGNED FTAs which restrict access to affordable
medicines, to immediately review & reverse all such provisions in their FTAs and rollback harmful laws and policies
that are preventing access to affordable medicines.

ALL GOVERNMENTS to immediately end secrecy around FTA negotiations, make negotiating texts available for
public scrutiny & to support through open, transparent & public consultations assessments of the impact of such
negotiations on the right to health & other rights.

ALL PARLIAMENTS & CONTITUTIONAL BODIES to immediately request FTA negotiating texts; review their impact on
the right to health & access to medicines; refuse to endorse or ratify any FTAs that have been signed with provisions
that undermine their people’s right to access affordable treatment; and review all local laws including patent and
medicine regulatory laws and policies to ensure all aspects and elements of the Doha Declaration are in these laws.

UNAIDS & THE UN SYSTEM to go beyond issuing a statement & craft a proactive strategy to support the right to
health in this context; make this issue a key topic at all up-coming events & High Level meetings, ensure full
representation of community representatives & health groups at these events, analyse the effects of potential trade
agreements on access to medicines, share this analysis publicly & provide technical assistance to governments &
civil society to ensure that FTAs do not undermine human rights. Specifically, UNAIDS must unequivocally condemn
and urgently work to prevent the signing of FTAs that include any TRIPS-plus measures if they truly want to scaleup
access to treatment, prevent 1 million new infections annually and if Treatment 2.0 is to actually succeed.

The GLOBAL FUND BOARD to call attention to & condemn FTA negotiations that include TRIPS-plus measures, to
direct the Global Fund secretariat to assess the financial impact of potential trade agreements, share this analysis
publicly, & ensure the adoption of procurement systems that make optimal use of TRIPS flexibilities including
encouraging countries to use compulsory licences to ensure the GFATM does not pay excessive premiums for
patented medicines.

The WORLD HEALTH ORGANIZATION to stop retreating from its policy work on intellectual property & access to
medicines, to ensure that the WHO does not become a proponent of TRIPS-plus measures & to actively support &
encourage countries in using their rights in TRIPS to protect health & promote access to medicines for all.

CIVIL SOCIETY GROUPS, PEOPLE LIVING WITH HIV, ALL COMMUNITIES FACING COMMUNICABLE, CHRONIC &/OR
NON-COMMUNICABLE DISEASES in the North & the South to join forces to halt any & all trade agreements that
restrict access to generic medicines.
We stand in solidarity with all other peoples & movements whose rights to life, health, livelihood, equality,
equity, food, environment, knowledge, traditional systems of life & livelihood will also be negatively impacted by
these free trade agreements that threaten to widen the gap between the rich & the poor not only between
countries but within countries as well.

SIGNATORIES :
Anand Chabungbam, Asian Network of People who Use Drugs (ANPUD)
Andrew Hunter, Asia Pacific Network of Sex Workers (APNSW)
Andrew Tan, myPlus (Malaysian Positive Network), Malaysia
Apiwat Kwangkaew, Thai Network of People Living with HIV/AIDS (TNP+)
Aree Kumpitak, AIDS ACCESS Foundation, Thailand
Basanta Chettri, National Association of PLHA in Nepal (NAP+N), Nepal
Chalermsak Kittitrakul , AIDS ACCESS Foundation, Thailand
Catherine Tomlinson, Treatment Action Campaign (TAC), South Africa
Chen Yun Ji, International Treatment Preparedness Coalition (ITPC) – China
Dean Lewis, Asian Network of People who Use Drugs (ANPUD)
Denovan Abdullah, Jaringan Orang Terinfeksi HIV Indonesia (JOTHI), Indonesia
Do Dang Dong, Vietnam Network of Positive People
Edward Low, Positive Malaysian Treatment Access and Advocacy Group (MTAAG+), Malaysia
Francisco Rossi, Ifarma, Colombia
Giten Khwairakpam, Coalition of Asia Pacific Regional Network on HIV/AIDS (7 sisters)
Gregory Vergus, International Treatment Preparedness Coalition (ITPC) –Russia
Habiba Akhtar, Bangladesh Network of Positive People
Henan Wajahat, Association of People Living with HIV, Pakistan
Heng Phin, Cambodian People Living with HIV/AIDS Network (CPN+)
Heru, Jaringan Orang Terinfeksi HIV Indonesia (JOTHI), Indonesia
Imran Zali, Association of People Living with HIV, Pakistan
Kajal Bhardwaj, Independent Lawyer (HIV, health and human rights), India
Kannikar Kijtiwatchakul, Health Consumers Protection Program, Thailand
Karyn Kaplan, Thai AIDS Treatment Action Group (TTAG), Thailand
K.M. Gopakumar, Third World Network
Loon Gangte, Delhi Network of Positive People (DNP+), India
Lorena Di Giano, Argentinean Network of women Living with HIV/AIDS
Lu Hong Wei, International Treatment Preparedness Coalition (ITPC) – China
Manoj Pardeshi, International Treatment Preparedness Coalition (ITPC) – India
Masayoshi Tarui, Japan AIDS & Society Association, Japan
Matthew Kavanagh, HealthGap, United States
Mony Pen, Cambodian Community of Women Living with HIV
Naresh Yadav, Uttar Pradesh Network of People Living With HIV/AIDS (UPNP+), India
Nimit Tian-Udom, AIDS ACCESS Foundation, Thailand
Noah Metheny, Thai AIDS Treatment Action Group (TTAG), Thailand
Olga Stefanyshyna, Ukrainian Network of Positive People
Omar Syarif, Jaringan Orang Terinfeksi HIV Indonesia (JOTHI), Indonesia
Pauline Londeix, Act-Up Paris
Quinto Noel, Pinoy Plus Association (PPA+), Philippines
Rose Kaberia, International Treatment Preparedness Coalition (ITPC) – Eastern Africa
Sangsiri Trimanka, AIDS ACCESS Foundation, Thailand
Sarah Zaidi, International Treatment Preparedness Coalition (ITPC) – Thailand
Shiba Phurailatpam, Asia Pacific Network of People Living with HIV/AIDS (APN+)
Surendra Shah, Navakiran Plus, Nepal
Thiha Kyaing, Myanmar Positive Group
Vince Crisostomo, Coalition of Asia Pacific Regional Network on HIV/AIDS (7 sisters)